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Introduction: EML4-ALK is a driver oncogene in non–small-
cell lung cancer (NSCLC) and has been developed into a promis-
ing molecular target for antitumor agents. Although EML4-ALK is 
reported to be formed by inversion of chromosome 2, other mecha-
nisms of this gene fusion remain unknown. This study aimed to 
examine the mechanism of EML4-ALK rearrangement using a novel 
cell line with the EML4-ALK fusion gene.
Methods: An EML4-ALK-positive cell line, termed JFCR-LC649, was 
established from pleomorphic carcinoma, a rare subtype of NSCLC. 
We investigated the chromosomal aberrations using fluorescence in situ 
hybridization and comparative genomic hybridization (CGH). Alectinib/
CH5424802, a selective ALK inhibitor, was evaluated in the antitumor 
activity against JFCR-LC649 in vitro and in vivo xenograft model.
Results: We established an EML4-ALK-positive cell line, termed 
JFCR-LC649, derived from a patient with NSCLC and revealed that 
the JFCR-LC649 cells harbor variant 3 of the EML4-ALK fusion with 
twofold copy number gain. Interestingly, comparative genomic hybrid-
ization and metaphase-fluorescence in situ hybridization analysis 
showed that in addition to two normal chromosome 2, JFCR-LC649 
cells contained two aberrant chromosome 2 that were fragmented and 
scattered. These observations provided the first evidence that EML4-
ALK fusion in JFCR-LC649 cells was formed in chromosome 2 by a 
distinct mechanism of genomic rearrangement, termed chromothrip-
sis. Furthermore, a selective ALK inhibitor alectinib/CH5424802 
suppressed tumor growth of the JFCR-LC649 cells through inhibition 
of phospho-ALK in vitro and in vivo in a xenograft model.
Conclusion: Our results suggested that chromothripsis may be a 
mechanism of oncogenic rearrangement of EML4-ALK. In addition, 
alectinib was effective against EML4-ALK-positive tumors with ALK 
copy number gain mediated by chromothripsis.
Key Words: ALK, Lung cancer, Chromosomal rearrangement, 
Chromothripsis, ALK inhibitor.
(J Thorac Oncol. 2014;9: 1638–1646)
Tyrosine kinase fusion genes have been identified in some cancers, and the constitutive activation of these fusion 
kinases is involved in tumorigenesis. BCR-ABL fusion gene 
was found in chronic myelogenous leukemia, and the ABL 
inhibitor imatinib is a successful drug for chronic myelogenous 
leukemia patients.1 In addition to BCR-ABL, the ALK, ROS1, 
and RET fusion genes have recently been identified as driver 
oncogenes in non–small-cell lung cancer (NSCLC).2–5 The 
tumorigenic potential of these fusion genes, namely EML4-
ALK, CD74-ROS1, and KIF5B-RET, was confirmed using a 
transformation assay via subcutaneous injection of the trans-
fected 3T3 cells into nude mice.2,3 Of those, patients with ALK 
fusion-positive NSCLC have responded in clinic to treatment 
with ALK inhibitors.6–8 In addition, crizotinib has recently 
demonstrated its efficacy in the treatment of NSCLC with 
ROS1 translocations.9 Furthermore, in a prospective phase 2 
trial that included RET fusion-positive NSCLC patients, two 
patients with RET fusion-positive NSCLC responded to cabo-
zantinib.10 Thus, fusion genes are considered to be promising 
targets for anticancer therapy.
Most of the fusion genes are generated by chromosomal 
rearrangements, such as translocation or inversion. Although 
the genetic alterations in tumorigenesis can accumulate gradu-
ally over time, a recent study has revealed a new phenomenon 
in which tens to hundreds of chromosomal rearrangements are 
acquired simultaneously by a single catastrophic event.11 This 
phenomenon, termed chromothripsis, can be seen in at least 2 
to 3% of all cancers and is often believed to promote tumori-
genesis in a wide variety of tumors: indeed, chromothripsis 
is associated with a more aggressive clinical course in neu-
roblastoma, multiple myeloma, colorectal cancer, and medul-
loblastoma.12–15 Chromothripsis may result in chromosomal 
rearrangement and copy number changes, including deletion 
of tumor suppressor genes and amplification of oncogenes. 
In one neuroblastoma tumor, chromothripsis resulted in 
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amplification and very strong overexpression of c-Myc.12 In 
addition, two different medulloblastoma tumors have translo-
cation of PVT1, including PVT1-MYC and PVT1-NDRG, that 
arose via chromothripsis.16
EML4-ALK results from a small inversion within chromo-
some 2p, which leads to the expression of a chimeric tyrosine 
kinase, in which the N-terminus of EML4 is fused to the intra-
cellular kinase domain of ALK.2 However, the detailed mecha-
nisms of EML4-ALK rearrangement remain unknown. Here, we 
explore the mechanism of EML4-ALK rearrangement using a 
novel cell line with the EML4-ALK fusion gene, considering a 
potential role of chromothripsis for the fusion formation.
PATIENTS AND METHODS
Compounds and Cell Lines
Alectinib/CH5424802 was synthesized at Chugai 
Pharmaceutical Co., Ltd. according to the procedure described 
in patent publication WO2010143664. Crizotinib was purchased 
from Selleck Chemicals (Houston, TX) and gefitinib was pur-
chased from Kemprotec Limited (Lancashire, UK) JFCR-LC649 
cells were established at the Japanese Foundation for Cancer 
Research (JFCR) from a treatment-naive female NSCLC patient. 
NCI-H2228 and NCI-H522 cells were obtained from American 
Type Culture Collection (Rockville, MD). Generation of Ba/
F3 cells expressing EML4-ALK was described in our previous 
study.17 This study was approved by the research ethics commit-
tees of both JFCR and Chugai Pharmaceutical Co. Ltd.
RT-PCR and Direct Sequence
Total RNA was extracted using the RNeasy kit (Qiagen, 
Hilden, Germany), and reverse-transcriptase polymerase 
chain reaction (RT-PCR) analysis was performed with sets 
of primers (Supplementary Table 1, Supplemental Digital 
Content, http://links.lww.com/JTO/A678) to detect the EML4-
ALK variant. Direct sequence was done with ABI Prism 3100 
Genetic Analyzer (Applied Biosystems, Foster City, CA).
Fluorescent In Situ Hybridization
For ALK break-apart fluorescent in situ hybridization 
(FISH) experiments, formalin-fixed paraffin-embedded (FFPE) 
4-μm sections of JFCR-LC649 xenograft tumors were deparaf-
finized and treated with Pretreatment Reagent (Abbott Molecular, 
Inc., Des Plaines, IL) at 80°C for 10 minutes and then with pep-
sin solution (Zytovision, Bremerhaven, Germany) at 37°C for 10 
minutes. Vysis LSI ALK Dual Color, Break Apart Rearrangement 
Probe (Abbott Molecular, Inc.) was applied to detect ALK gene 
rearrangement. Slides and probes were denatured simultane-
ously at 75°C for 10 minutes, followed by hybridizing at 37°C 
overnight with Thermobrite (Abbott Molecular, Inc.). After 
stringent washing with 0.3% NP-40/2× SSC at 72°C for 2 min-
utes, slides were mounted with DAPI (Life Technologies, Grand 
Island, NY). For metaphase probe-FISH analysis, JFCR-LC649 
cells were incubated with Colcemid (Life Technologies) over-
night at 37°C. Cells were trypsinized and a hypotonic treatment 
was performed. Fixation was performed in Carnoy’s fixative, 
and this suspension was spread onto glass slides. Slides were 
denatured in 2× SSC/70% formamide at 68°C for 3 minutes, 
dehydrated through 70%, 90%, and 100% ethanol, and air-dried. 
FISH probes were denatured at 75°C for 10 minutes and applied 
onto slides, and then hybridized at 37°C overnight. Slides were 
washed and mounted with DAPI. Hybridization signals were 
captured with a fluorescence microscope (Eclipse E600; Nikon, 
Tokyo, Japan) equipped with appropriate filter sets. The 3′ 
ALK gene probe labeled with fluorescein isothiocyanate (GSP 
Laboratory, Kanagawa, Japan) was used in combination with 
a probe for the centromeric region of chromosome 2 labeled 
with SpectrumOrange (Abbott Molecular, Inc.). Metaphase 
probe-FISH analysis to verify the evidence of chromothripsis 
was performed as previously described.18 FISH probes were 
generated from DNA fragments that were amplified by PCR 
using 3 primer pairs covering a sequence region of up to 30 kb 
in size within a segment. The probe information is described in 
Supplementary Table S2 (Supplemental Digital Content, http://
links.lww.com/JTO/A678). These DNA fragments were labeled 
with biotin-16-dUTP or digoxigenin-11-dUTP using a labeling 
reagent for array-comparative genomic hybridization (CGH) 
analysis (Agilent Biosystems, Santa Clara, CA) and used for 
hybridization. Hybridization signals were detected by avidin-
fluorescein (Roche Applied Science, Indianapolis, IN) and fluo-
rescein anti-avidin antibody (Vector Laboratories, Burlingame, 
CA) for biotin-labeled probes and anti-digoxigenin antibody 
(Roche Applied Science, Indianapolis, IN) and Alexa 568 anti-
mouse IgG (Molecular Probes, Eugene, OR) for digoxigenin-
labeled probes. The images were recorded using a fluorescence 
microscope (Eclipse E600; Nikon) equipped with a digital 
camera (Ds-Ri1-U2; Nikon).
Immunohistochemistry
ALK immunohistochemistry (IHC) was performed 
with an ALK detection kit (Nichirei Biosciences, Inc., Tokyo, 
Japan). NSCLC cell lines were cultured on chamber slides 
(Iwaki, Chiba, Japan), fixed with cold 70% ethanol, permea-
bilized with 0.2% Triton X100/PBS, and used following the 
manufacturer’s procedure. Briefly, pre-diluted ALK mouse 
monoclonal antibody, 5A4 was applied and incubated for 30 
minutes at room temperature. After using a bridge reagent to 
amplify the signal horseradish peroxidase linked antibody 
and 3,3′-diaminobenzidine tetrahydrochloride were used for 
detection. Positivity in the culture cell image is recognized by 
brown staining compared with negative control, which did not 
show any irrelevant background staining.
FFPE 4-μm sections of JFCR-LC649 xenograft tumors 
were depleted of paraffin with xylene, rehydrated through a 
graded series of ethanol solutions, and subjected to immu-
nohistochemical staining with a mouse monoclonal antibody 
of Napsin A (IP64, Novocastra, Newcastle, UK), E-cadherin 
(NCH-38, Dako, Glostrup, Denmark), vimentin (V9, Dako), 
or TTF-1 (8G7G3/1, Dako) or with a rabbit polyclonal anti-
body of p40 (5-17, Calbiochem, Billerica, MA). Heat-induced 
antigen retrieval pretreatment was performed with Bond 
Epitope Retrieval solution 2 pH 9.0 (Leica, Newcastle, UK).
Array-Based Comparative Genomic Hybridization
The PCR-amplified DNA and the control DNA were sep-
arately labeled with Cy5-dUTP and Cy3-dUTP, respectively, 
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then mixed and hybridized to human genome 244K standard 
microarrays or SurePrint G3 human CGH arrays containing 
974,000 probes (Agilent Technologies) according to the man-
ufacturer’s protocol. The procedure for labeling of DNA and 
hybridization to microarrays is described in the manufacturer’s 
instructions. Fold changes in the hybridization signal intensi-
ties of sample genomic DNA relative to the normal genomic 
DNA were visualized using Genomic Workbench software 
(Agilent Technologies) and SignalMap software (Nimblegen 
Systems, Inc., Madison, WI).
Cell Growth Inhibition and Caspase-3/7 Assay
Cells were cultured in 96-well spheroid plates (Sumilon 
Celltight Spheroid 96U; Sumitomo Bakelite, Inc., Tokyo, 
Japan) overnight and incubated with various concentrations of 
compound for the indicated time. The viable cells were mea-
sured by the CellTiter-Glo luminescent cell viability assay 
(Promega, Fitchburg, WI). Caspase-3/7 assay was evaluated 
using the Caspase-Glo 3/7 Assay Kit (Promega). Fluorescence 
was quantified using Envision (PerkinElmer, Waltham, MA).
Immunoblotting and Immunoprecipitation
Cells were lysed in Cell Lysis Buffer (Cell Signaling 
Technology) containing 1 mM PMSF, 1% (v/v) phosphate 
inhibitor cocktail 1 (Sigma-Aldrich, St. Louis, MO), 1% 
(v/v) phosphate inhibitor cocktail 2 (Sigma), and Complete 
Mini, EDTA-Free 1 (Roche Applied Science). Cell lysates 
were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis, and the separated proteins were electropho-
retically transferred to Immobilon-P membranes (Millipore). 
After blocking in Blocking One (Nacalai Tesque, Inc.), the 
membranes were incubated independently in the primary 
antibodies diluted with anti-ALK (Life Technologies, #51-
3900), anti-STAT3 (Cell Signaling Technology, #9132; Cell 
Signaling Technologies, Danvers, MA), anti-Phospho-STAT3 
(Tyr 705; Cell Signaling Technology, #9131), anti-AKT (Cell 
Signaling Technology, #9277), anti-Phospho-AKT (Ser 473; 
Cell Signaling Technology, #9271), anti-p44/42 MAP Kinase 
(ERK1/2; Cell Signaling Technology, #9102), or anti-Phos-
pho-ERK1/2 (Thr 202/Tyr 204; Cell Signaling Technology, 
#9101). To detect phosphorylated ALK, cell lysates were 
immunoprecipitated with anti-phosphotyrosine (PY-20) 
antibody (BD Biosciences, San Jose, CA). The immunopre-
cipitants were then collected with Protein G sepharose (GE 
Healthcare, Waukesha, WI) and subjected to immunoblot 
analysis using an anti-ALK antibody. The membranes were 
incubated with an anti-rabbit HRP-linked antibody (Cell 
Signaling Technology). The bands were detected with ECL-
plus (GE Healthcare) or Chemi-Lumi One Super (Nacalai 
Tesque, Inc.) followed by LAS-4000 (Fujifilm, Tokyo, Japan).
In Vivo Studies
Cell lines were used to evaluate the antitumor activity 
of alectinib in vivo. They were grown as subcutaneous tumors 
in SCID mice (CLEA Japan, Inc., Tokyo, Japan) that were 
then randomized to treatment groups to receive vehicle or 
alectinib (oral, qd) for the indicated duration. Final concentra-
tion of vehicle was 0.02N HCl, 10% DMSO, 10% Cremophor 
EL, 15% PEG400, and 15% HPCD (2-hydroxypropyl-β-
cyclodextrin). The length (L) and width (W) of the tumor mass 
were measured, and the tumor volume (TV) was calculated 
as: TV = (L × W2)/2. Tumor growth inhibition was calculated 
using the following formula: Tumor growth inhibition = [1 − 
(T − T
0
)/(C − C
0
)] × 100, where T and T
0
 are the mean tumor 
volumes on a specific experimental day and on the first day of 
treatment, respectively, for the experimental groups and like-
wise, where C and C
0
 are the mean tumor volumes for the 
control group. The rate of change in body weight (BW) was 
calculated using the following formula: BW = W/W
0
 × 100, 
where W and W
0
 are the body weight on a specific experimen-
tal day and on the first day of treatment, respectively. All ani-
mal experiments in this study were performed in accordance 
with protocols approved by the Institutional Animal Care and 
Use Committee (IACUC) of Chugai Pharmaceutical Co., Ltd.
RESULTS
Characterization of the Novel  
EML4-ALK-Positive NSCLC Cell Line
We established a novel cell line, termed JFCR-LC649, 
which was derived from an ALK-positive, chemotherapy-
naive, female NSCLC patient, who had never smoked. First, 
we conducted IHC on mouse xenograft tumors of JFCR-LC649 
cells to detect the expression of TTF-1 and Napsin A (as 
markers of type II pneumocytes),19,20 vimentin (as a marker of 
mesenchymal cells),21,22 E-cadherin (as a marker of epithelial 
cells),21,22 and p40 (as a marker of basal cells or squamous cell 
carcinoma).23 From these stainings, we found that the xeno-
graft tumors were positive for TTF-1, Napsin A, vimentin, 
and E-cadherin but negative for p40 (Supplementary Figure 
S1, Supplemental Digital Content, http://links.lww.com/JTO/
A678), indicating that JFCR-LC649 cells were associated 
with a phenotype characterized by lung adenocarcinoma cells 
undergoing epithelial–mesenchymal transition.
Next, to determine ALK status in JFCR-LC649 cells, 
we performed ALK IHC analysis and RT-PCR analysis. ALK 
IHC analysis confirmed that JFCR-LC649 cells expressed 
ALK protein (Fig. 1A), and RT-PCR analysis showed that 
they have EML4-ALK variant 3, which is exactly the same 
EML4-ALK variant as in NCI-H2228 (Fig. 1B, Supplementary 
Figure S2A, Supplemental Digital Content, http://links.lww.
com/JTO/A678). Sequencing of the JFCR-LC649 transcript 
showed that it was the product of EML4-ALK variant 3, and 
that there were no mutations of the ALK kinase domain 
(Supplementary Figure S2B, Supplemental Digital Content, 
http://links.lww.com/JTO/A678).
Furthermore, we performed ALK break-apart FISH assays 
to confirm the chromosomal rearrangement in JFCR-LC649 
cells. Interestingly, JFCR-LC649 cells have twofold ALK 
copy number gain compared with conventional cytogenetics, 
as well as the EML4-ALK fusion gene (Fig. 1C). From 244K 
array-based CGH analysis, we confirmed that JFCR-LC649 
cells have a twofold ALK copy number gain compared with 
normal cells and, in addition, have an extremely unusual pat-
tern of allelic changes or “allele number oscillation” in chro-
mosome 2, on which ALK is located (Fig. 1D, Supplementary 
Figures S3 and S4, Supplemental Digital Content, http://links.
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lww.com/JTO/A678). On the other hand, another EML4-
ALK-positive cell line, NCI-H2228, does not have this unique 
chromosome 2 (Fig. 1D). In addition, a good concordance of 
copy number profile for chromosome 2 between JFCR-LC649 
cells and the corresponding original tumor materials was 
observed (Supplementary Figure S5, Supplemental Digital 
Content, http://links.lww.com/JTO/A678). Such a phenom-
enon can be seen in the specific chromosomal loci in some 
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FIGURE 1.  Characterization of patient-derived cell line JFCR-LC649. A, In IHC analysis for ALK, both JFCR-LC649 and NCI-
H2228 cells were positive for ALK. NCI-H522 cells were used as a negative control. B, In EML4-ALK fusion-specific RT-PCR, 
JFCR-LC649 cells expressed EML4-ALK variant 3. NCI-H2228 cells harboring EML4-ALK variant 3, Ba/F3 cells transfectant EML4-
ALK variant 1, and water as a negative control were used. C, In the ALK break-apart FISH assay, separate 3′ALK signals (red) 
and 5′ALK signals (green) individually existed, indicating that JFCR-LC649 cells harbored ALK rearrangement. JFCR-LC649 cells 
contained two ALK fusion-positive chromosome 2 (indicated with yellow arrows) and two ALK fusion-negative chromosome 2 
(indicated with red arrows). D, 244K array-based CGH analysis shows the ALK copy number gain and distinct chromosomal pat-
tern in chromosome 2 of JFCR-LC649 cells.
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clinical samples and in cell lines involved in a one-off cata-
strophic event termed chromothripsis.11–15,24 Thus, this unique 
chromosome 2 of JFCR-LC649 cells could correspond to the 
phenomenon of chromothripsis.
EML4-ALK Rearrangement Mediated 
by Chromothripsis in JFCR-LC649
Chromothripsis is a phenomenon in which tens to 
hundreds of chromosomal rearrangements can be generated 
simultaneously via a single catastrophic event. Stephens et 
al.11 describe that the number of copy number states within 
the areas caused by chromothripsis oscillates between one and 
two (and occasionally three). To verify whether JFCR-LC649 
cells harbor this hallmark of chromothripsis, we conducted 
1M array-based CGH analysis (high-resolution array-CGH 
analysis). Within chromosome 2 of JFCR-LC649 cells, an 
oscillating pattern between two copy number states was reca-
pitulated (Fig. 2A), suggesting that JFCR-LC649 cells harbor 
chromothripsis-derived characteristic chromosome 2.
To confirm that chromosome 2 of JFCR-LC649 cells 
were mediated by chromothripsis, we examined metaphase 
chromosome spread from JFCR-LC649 cells that was ana-
lyzed using a 3′ALK probe in combination with the probe for 
the centromeric region of chromosome 2 to understand the 
number and size of chromosome 2. We found that, in addition 
to two normal chromosome 2, JFCR-LC649 cells contained 
two aberrant chromosome 2, that were shorter than the length 
of its normal chromosome 2 (Fig. 2B). On the other hand, 
normal lymphocytes contained two normal chromosome 2 
(Supplementary Figure S6, Supplemental Digital Content, 
http://links.lww.com/JTO/A678). These data were similar to 
a previous report that TK10 (a renal cancer cell line) with 
genomic landscapes harboring the hallmarks of chromothrip-
sis showed four grossly normal copies of chromosome 5 and 
two smaller derivative chromosomes.11 To further understand 
the aberrant chromosome 2 in JFCR-LC649 cells, we con-
ducted metaphase-FISH analysis using a probe with a red sig-
nal and 2 different kinds of probes with green signals designed 
by using the data from the 1M array-based CGH analysis (Fig. 
2D). These probe sets target adjacent regions of the genome 
in normal chromosome 2. All signals existed in the same posi-
tions in normal chromosome 2, but the green signals split in 
aberrant chromosome 2, indicating that fragmentation and 
scattering of the chromosome had occurred (Fig. 2C).11 These 
results indicated that the aberrant chromosomes were gen-
erated by chromothripsis. Thus, these observations provide 
us the first evidence that EML4-ALK in chromosome 2 of 
JFCR-LC649 cells was mediated by chromothripsis (Fig. 3).
Potency of ALK Inhibitor Alectinib Against 
JFCR-LC649 Cells with ALK Copy Number Gain
Previous reports showed that copy number gain of 
EML4-ALK has been observed both in cell lines and in patient 
tumors as an additional mechanism of crizotinib resistance in 
ALK-positive NSCLC.25,26 To clarify the sensitivity to ALK 
inhibitors against the cell lines with ALK copy number gain, 
we tested the cell growth inhibitory effect of a selective ALK 
inhibitor alectinib,17 or crizotinib against JFCR-LC649 cells. 
Alectinib and crizotinib both inhibited the cell growth of 
JFCR-LC649 cells, and the potency of alectinib was approxi-
mately 13-fold more potent than that of crizotinib (Fig. 
4A). On the other hand, an EGFR inhibitor gefitinib did not 
inhibit its growth (Fig. 4A). In addition, alectinib induced 
caspase-3/7 activation in JFCR-LC649 cells (Fig. 4B), indi-
cating that apoptosis induction is involved in the antitumor 
activity of alectinib. To understand the effect of phospho-
ALK suppression and the contribution of ALK downstream 
components, we conducted a cellular phosphorylation assay 
using JFCR-LC649 cells that had been treated with alec-
tinib. Alectinib suppressed auto-phosphorylation of ALK in 
a concentration-dependent manner (Fig. 4C). In addition, 
alectinib also suppressed phosphorylation of STAT3 but did 
not suppress phosphorylation of AKT and ERK1/2 (Fig. 4C). 
The inhibitory activity on phospho-STAT3 and the apoptosis-
inducing activity of crizotinib are weaker than those of alec-
tinib (Supplementary Figure S7A, B, Supplemental Digital 
Content, http://links.lww.com/JTO/A678).
We next tested the efficacy of alectinib and crizotinib 
in a mouse xenograft model of JFCR-LC649 cells. Although 
the engraftment of JFCR-LC649 cells took a long time, 
IHC analysis showed that JFCR-LC649 xenograft tumors 
still expressed ALK protein 101 days after the inoculation 
(Fig. 5A). Using this xenograft model, we confirmed that 
once-daily oral administration of alectinib resulted in remark-
able tumor regression at all dose levels (p < 0.001, alectinib 
versus vehicle treatment using parametric Dunnett’s test) 
without significant body weight loss (Fig. 5B) and its nearly 
equal activity against another EML4-ALK-positive cell line, 
NCI-H2228, has already been observed.17 Crizotinib at the 
maximum tolerated dose (MTD: 100 mg/kg) in mice27 also 
resulted in remarkable tumor regression against JFCR-LC649 
bearing mice models (Fig. 5B). In the phosphorylation assay 
of the JFCR-LC649 xenograft tumors, both alectinib and 
crizotinib suppressed auto-phosphorylation of ALK in vivo 
(Fig. 5C). Taken together, we confirmed both in vitro and in 
vivo in a xenograft model that both alectinib and crizotinib 
were effective against EML4-ALK-positive tumors with ALK 
copy number gain mediated by chromothripsis.
DISCUSSION
We obtained the first evidence that chromothripsis 
is one of the formation mechanisms of EML4-ALK rear-
rangement. Although several groups have observed chro-
mothripsis in various cancers, there is little information on 
the link between oncogenic fusion genes and chromothripsis. 
Northcott et al.16 identified that PVT1-MYC and PVT1-NDRG 
arose via chromothripsis in each of two different tumors of 
medulloblastoma. In addition, Wu et al.28 found evidence 
of chromothripsis in a patient-derived prostate tumor with 
TMPRSS2-ERG, which is known as a key fusion gene leading 
to multigenic events in prostate cancer. Recently, Cazes et al.29 
analyzed the whole genome sequence and reported that the 
chromosome with ALK locus of one neuroblastoma sample 
was related to the phenomenon of chromothripsis, but this 
ALK fusion was not in-frame. In 2007, Soda et al.2 provided 
evidence that it remained undetermined whether the NSCLC 
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FIGURE 2.  Chromosomal structure analysis of JFCR-LC649 cells. A, 1M array-based CGH profile of chromosome 2 in 
JFCR-LC649 cells. An oscillating pattern between two copy number states was observed within chromosome 2 of JFCR-LC649 
cells. B, FISH analysis of a metaphase chromosome spread in JFCR-LC649 cells using probes of the centromeric region of chro-
mosome 2 (red) and 3′ALK (green). JFCR-LC649 cells contained two aberrant chromosome 2 (indicated with yellow arrows) and 
two normal chromosome 2 (indicated with red arrows). C, FISH analysis of a metaphase chromosome spread in JFCR-LC649 
cells using the dual color probe set (#1 probe, red; #4 and #6 probes, green). In normal chromosome 2, all signals existed in 
the same position but in aberrant chromosome 2 the green signal split, indicating fragmentation and scattering of the chromo-
some had occurred. D, Schematic representation of the three kinds of FISH probes (1, 4, and 6).
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cells of a patient with in-frame fusion of EML4-ALK harbor 
a simple inversion within chromosome 2p or whether they 
contain complex chromosome translocations involving 2p, 
implying that the mechanism of chromosomal rearrangement 
in EML4-ALK might be complicated. Therefore, we focused 
on investigating the relationship between ALK fusion genes 
and chromothripsis.
First, we evaluated the array-based CGH copy number 
profile of chromosome 2 in cell lines harboring ALK fusion 
gene and revealed that JFCR-LC649 cells harbored a chro-
mothripsis-like CGH pattern in chromosome 2 (Fig. 1D). We 
also analyzed EML4-ALK-positive NSCLC cell line NCI-
H2228 and NPM-ALK-positive anaplastic large cell lym-
phoma cell lines, such as KARPAS-299, SR, SUP-M2, L82, 
and SU-DHL-1, but did not find a chromothripsis-like pat-
tern (Fig. 1D and Supplementary Figure S8, Supplemental 
Digital Content, http://links.lww.com/JTO/A678). Next, to 
speculate on the occurrence of chromothripsis from the copy 
number profile in EML4-ALK-positive NSCLC, we analyzed 
Inversion 
ALK EML4
ALK EML4
Inversion 
Fragmentation 
Random rejoining 
ALK EML4
ALK EML4
Chromothripsis
FIGURE 3.  Model of EML4-ALK rearrangement mediated 
by inversion and chromothripsis. Chromothripsis causes a 
one-off catastrophic chromosome breakage and subsequent 
random reassembly of the chromosome fragments.
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FIGURE 4.  Efficacy of ALK inhibitor, alectinib against 
JFCR-LC649 cells. A, Growth inhibition of JFCR-LC649 cells by 
alectinib. Alectinib and crizotinib both inhibited cell growth of 
JFCR-LC649. Data are shown as mean ± SD (n = 3 per group). 
B, Increase in caspase 3/7 activity by alectinib in JFCR-LC649 
cells. Alectinib induced caspase 3/7 activity of JFCR-LC649 
cells in a concentration-dependent manner. Data are shown 
as mean ± SD (n = 3 per group). C, Effect of alectinib on the 
phosphorylation levels of ALK, STAT3, AKT, and ERK1/2 in 
JFCR-LC649 cells. Alectinib suppressed phosphorylation of ALK 
and STAT3 in a concentration-dependent manner but did not 
suppress phosphorylation of AKT and ERK1/2.
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FIGURE 5.  Antitumor activity of alectinib or crizotinib 
against a mouse xenograft model of JFCR-LC649 cells. A, 
JFCR-LC649 xenograft tumors 101 days after inoculation 
showed ALK-positive IHC staining. B, Alectinib or crizotinib 
once daily for 10 days at the indicated doses reduced the 
tumor volume without significant body weight change. Data 
are shown as mean ± SD (n = 4 per group). C, Mice bear-
ing JFCR-LC649 cells were orally administered a dose of 0 
(vehicle), 60 mg/kg alectinib, or 100 mg/kg crizotinib and the 
tumors were collected and lysed at 4 hours post-dosing. Both 
alectinib and crizotinib suppressed phosphorylation of ALK.
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an array-based CGH data set of five clinical samples derived 
from EML4-ALK-positive NSCLC patients from The Cancer 
Genome Atlas (TCGA). Interestingly, only one EML4-ALK-
positive case (TCGA-78-7163-11A-01D-2062-01) in TCGA 
showed a recurrent pattern of chromosomal aberration on 
the short arm of chromosome 2 (Supplementary Figure S9, 
Supplemental Digital Content, http://links.lww.com/JTO/
A678), suggesting that some EML4-ALK-positive cases 
might have chromosome 2 mediated by chromothripsis. Thus, 
chromothripsis might be one of the mechanisms of oncogenic 
rearrangement of EML4-ALK in NSCLC. Further investiga-
tion is needed to evaluate the relationship between EML4-
ALK rearrangement and chromothripsis.
Although several ALK inhibitors, such as crizotinib and 
alectinib, have demonstrated a clinical benefit against ALK 
fusion-positive lung adenocarcinoma patients, information on 
the effectiveness of these ALK inhibitors against other lung 
cancer subtypes than adenocarcinoma is limited because most 
ALK fusion-positive patients have adenocarcinoma histology. 
However, ALK rearrangements have also been seen, albeit to 
a much lesser extent, in other NSCLC.30,31 The JFCR-LC649 
cells we used were established from a surgically resected tumor 
specimen diagnosed as a rare subtype of NSCLC termed pul-
monary pleomorphic carcinoma, which generally shows a poor 
response to chemotherapy regimens.32 Histopathologically, a 
pulmonary pleomorphic carcinoma is defined as a tumor that 
combines spindle or giant cell carcinoma with any of the more 
usual patterns of NSCLC,32 and our case is composed of ade-
nocarcinoma and spindle cell carcinoma. Because we antici-
pated that we would be able to obtain a distinct cell line derived 
from the patient with pulmonary pleomorphic carcinoma con-
taining a component of adenocarcinoma, we conducted IHC 
on mouse xenograft tumors of JFCR-LC649 cells to detect 
the expression of TTF-1, Napsin A, vimentin, E-cadherin, and 
p40. As mentioned in the Results section, we found that the 
xenograft tumors were positive for TTF-1, Napsin A, vimentin, 
and E-cadherin but negative for p40 (Supplementary Figure 
S1, Supplemental Digital Content, http://links.lww.com/JTO/
A678), indicating that JFCR-LC649 cells were associated with 
a phenotype characterized by lung adenocarcinoma cells under-
going epithelial–mesenchymal transition. Thus, JFCR-LC649 
cells could be used to understand the efficacy of ALK inhibi-
tors against EML4-ALK rearranged pulmonary pleomorphic 
carcinoma with adenocarcinoma components. Needless to 
say, the case of JFCR-LC649 is not an exception because the 
International Association for the Study of Lung Cancer pro-
poses that ALK testing is recommended for adenocarcinomas 
and mixed lung cancers with an adenocarcinoma component.
Our study also has implications for the EML4-ALK 
downstream signaling pathway. We confirmed that alectinib 
was effective against JFCR-LC649 cells harboring EML4-
ALK, suppressing phosphorylation of STAT3 but not that of 
AKT and ERK1/2 in this cell (Fig. 4B). In our previous study, 
however, alectinib suppressed phosphorylation of AKT as well 
as that of STAT3 but did not suppress that of ERK1/2 in NCI-
H2228 cells expressing EML4-ALK.17 In addition, another 
ALK inhibitor NVP-TAE684 suppressed phosphorylation of 
STAT3 but not ERK1/2 in NCI-H2228 cells.33 However, in 
EML4-ALK-positive NCI-H3122 cells, both crizotinib and 
NVP-TAE684 suppressed phosphorylation of STAT3, AKT, 
and ERK1/2.25,34 Downstream components of EML4-ALK 
might depend on cell type; however, further detailed study is 
needed to evaluate the downstream signal of EML4-ALK.
ACKNOWLEDGMENTS
Parts of this study were supported financially by Grants-
in-Aid for Scientific Research from the Ministry of Education, 
Culture, Sports, Science and Technology, Japan, grants from 
the Japan Society for the Promotion of Science, the Ministry 
of Health, Labour and Welfare, and the Princess Takamatsu 
Cancer Research Fund, and Smoking Research Foundation.
REFERENCES
 1. Kantarjian H, Sawyers C, Hochhaus A, et al.; International STI571 CML 
Study Group. Hematologic and cytogenetic responses to imatinib mesyl-
ate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652.
 2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-
ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561–566.
 3. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in 
lung cancer. Nat Med 2012;18:378–381.
 4. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adeno-
carcinoma. Nat Med 2012;18:375–377.
 5. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and 
RET gene fusions from colorectal and lung cancer biopsies. Nat Med 
2012;18:382–384.
 6. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhi-
bition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–1703.
 7. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib 
in patients with ALK-positive non-small-cell lung cancer: updated results 
from a phase 1 study. Lancet Oncol 2012;13:1011–1019.
 8. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with 
ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a 
single-arm, open-label, phase 1-2 study. Lancet Oncol 2013;14:590–598.
 9. Ou SH, Bang YJ, Camidge DR, et al. Efficacy and safety of crizotinib 
in patients with advanced ROS1-rearranged non-small cell lung cancer 
(NSCLC). J Clin Oncol 2013;31 (suppl; abstr 8032).
 10. Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in 
patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 
2013;3:630–635.
 11. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement 
acquired in a single catastrophic event during cancer development. Cell 
2011;144:27–40.
 12. Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neuro-
blastoma identifies chromothripsis and defects in neuritogenesis genes. 
Nature 2012;483:589–593.
 13. Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S. Chromothripsis 
identifies a rare and aggressive entity among newly diagnosed multiple 
myeloma patients. Blood 2011;118:675–678.
 14. Kloosterman WP, Hoogstraat M, Paling O, et al. Chromothripsis is a com-
mon mechanism driving genomic rearrangements in primary and meta-
static colorectal cancer. Genome Biol 2011;12:R103.
 15. Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediat-
ric medulloblastoma links catastrophic DNA rearrangements with TP53 
mutations. Cell 2012;148:59–71.
 16. Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural vari-
ation across 1,000 medulloblastoma genomes. Nature 2012;488:49–56.
 17. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selec-
tive ALK inhibitor capable of blocking the resistant gatekeeper mutant. 
Cancer Cell 2011;19:679–690.
 18. Kitada K, Aida S, Aikawa S. Coamplification of multiple regions of chro-
mosome 2, including MYCN, in a single patchwork amplicon in cancer 
cell lines. Cytogenet Genome Res 2012;136:30–37.
 19. Johansson L. Histopathologic classification of lung cancer: Relevance 
of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol 
2004;8:259–267.
1646 Copyright © 2014 by the International Association for the Study of Lung Cancer
Kodama et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 11, November 2014
 20. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription fac-
tor-1 expression in carcinomas of the lung, breast, pancreas, colon, kid-
ney, thyroid, and malignant mesothelioma. Hum Pathol 2010;41:20–25.
 21. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histo-
logical evolution of lung cancers acquiring resistance to EGFR inhibitors. 
Sci Transl Med 2011;3:75ra26.
 22. Devarajan E, Song YH, Krishnappa S, Alt E. Epithelial-mesenchymal 
transition in breast cancer lines is mediated through PDGF-D released by 
tissue-resident stem cells. Int J Cancer 2012;131:1023–1031.
 23. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DeltaNp63) is 
superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. 
Mod Pathol 2012;25:405–415.
 24. Kitada K, Taima A, Ogasawara K, Metsugi S, Aikawa S. Chromosome-
specific segmentation revealed by structural analysis of individually iso-
lated chromosomes. Genes Chromosomes Cancer 2011;50:217–227.
 25. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome 
crizotinib resistance in non-small cell lung cancers harboring the fusion 
oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011;108:7535–7540.
 26. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired 
crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 
2012;4:120ra17.
 27. Kuromitsu S, Mori M, Shimada I, et al. Anti-tumor activity of ASP3026, –A 
novel and selective ALK inhibitor. Cancer Res 2011;71 (suppl; abstr 2821).
 28. Wu C, Wyatt AW, McPherson A, et al. Poly-gene fusion transcripts 
and chromothripsis in prostate cancer. Genes Chromosomes Cancer 
2012;51:1144–1153.
 29. Cazes A, Louis-Brennetot C, Mazot P, et al. Characterization of rearrange-
ments involving the ALK gene reveals a novel truncated form associated 
with tumor aggressiveness in neuroblastoma. Cancer Res 2013;73:195–204.
 30. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase 
immunoreactivity correlates with ALK gene rearrangement and tran-
scriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 
2009;40:1152–1158.
 31. Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually 
exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients 
with non-small cell lung cancer. Clin Cancer Res 2013;19:4273–4281.
 32. Rossi G, Cavazza A, Sturm N, et al. Pulmonary carcinomas with 
pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopatho-
logic and immunohistochemical study of 75 cases. Am J Surg Pathol 
2003;27:311–324.
 33. Tanizaki J, Okamoto I, Takezawa K, et al. Combined effect of ALK and 
MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells. 
Br J Cancer 2012;106:763–767.
 34. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene 
and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 
2008;14:4275–4283.
